Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 325
interventional 250
Observational 72
Registry 3

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 115
Drug|placebo 60
Biological 20
Other 12
Behavioral 8
Biological|placebo 6
Device 5
Device|Other 3
Dietary Supplement 3
Dietary Supplement|placebo 3
Procedure 3
Biological|Drug 2
Other|placebo 2
Behavioral|Drug|placebo|Procedure 1
Biological|Drug|Other 1
Biological|Drug|placebo 1
Biological|Procedure 1
Dietary Supplement|Drug|placebo 1
Drug|Other 1
Drug|Other|Procedure 1
Drug|Procedure 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 52
NA 25
France 16
Germany 13
Italy 8
United States|Canada 7
Australia 5
United Kingdom 5
Iran, Islamic Republic of 4
Canada 3
Japan 3
Russian Federation 3
Spain 3
Switzerland 3
Turkey 3
Czech Republic|Germany|Hungary|India|Poland|Russian Federation|Ukraine|United Kingdom 2
Czech Republic|Russian Federation|Ukraine 2
Israel 2
Norway 2
Sweden 2
United States|Belgium|Bulgaria|Czechia|Germany|Kuwait|Latvia|Lebanon|Poland|Turkey 2
United States|Canada|Finland|Germany|Hungary|Italy|Norway|Poland|Russian Federation|Spain|Switzerland|Turkey 2
United States|United Kingdom 2
Argentina|Brazil|Colombia|Jordan|Malaysia|Mexico|Panama|Peru 1
Australia|Austria|Canada|Finland|France|Germany|Italy|Netherlands|New Zealand|Norway|Poland|Russian Federation|Spain|United Kingdom 1
Australia|Belgium|Canada|Czech Republic|Estonia|Finland|France|Germany|Greece|Hungary|Ireland|Israel|Netherlands|Poland|Romania|Russian Federation|Slovakia|South Africa|Sweden|Switzerland|Turkey|United Kingdom 1
Australia|Belgium|Canada|Czech Republic|Finland|France|Germany|Greece|Israel|Lithuania|Netherlands|Poland|Russian Federation|Slovakia|South Africa|Sweden|Switzerland|Turkey|United Kingdom 1
Australia|Belgium|Czechia|Denmark|Estonia|Finland|France|Germany|Ireland|Italy|Netherlands|Norway|Spain|Sweden|Switzerland|Turkey|United Kingdom 1
Australia|New Zealand 1
Australia|Spain 1
Australia|United States|Austria|Belarus|Belgium|Bosnia and Herzegovina|Bulgaria|Canada|Croatia|Czechia|Estonia|France|Germany|Greece|India|Ireland|Israel|Italy|Latvia|Mexico|Moldova, Republic of|Netherlands|New Zealand|North Macedonia|Poland|Puerto Rico|Romania|Serbia|Slovakia|South Africa|Spain|Switzerland|Ukraine|United Kingdom 1
Austria 1
Austria|Belgium|Canada|Czechia|France|Hungary|Italy|Portugal|Slovakia|Slovenia|Spain 1
Austria|Denmark|Estonia|Finland|Germany|Italy|Latvia|Lithuania|Netherlands|Norway|Portugal|Switzerland 1
Belarus|Croatia|Georgia|Moldova, Republic of|Poland|Serbia|Ukraine 1
Belgium|Bulgaria|Canada|Croatia|Czech Republic|Finland|Germany|Hungary|Italy|Lithuania|Poland|Russian Federation|Serbia|Spain|Switzerland|Turkey|Ukraine|United Kingdom 1
Belgium|Bulgaria|Canada|Croatia|Czech Republic|Finland|Germany|Hungary|Italy|Lithuania|Poland|Russian Federation|Serbia|Spain|Turkey|Ukraine|United Kingdom 1
Belgium|Denmark|Finland|Netherlands|Norway|Sweden|Switzerland|United Kingdom 1
Belgium|France|Germany|Italy|Spain 1
Belgium|Germany|Poland|Russian Federation|Spain 1
Belgium|Luxembourg|United Kingdom 1
Belgium|Mexico|Poland|Romania|Saudi Arabia|Ukraine 1
Bulgaria|Canada|Czech Republic|Germany|Spain|Sweden|Ukraine|United Kingdom 1
Bulgaria|Croatia|Czechia|Estonia|Germany|Hungary|Italy|Poland|Russian Federation|Serbia|Spain|Ukraine 1
Bulgaria|Czechia|Poland|Russian Federation|Serbia|Slovakia|Spain|Ukraine 1
Bulgaria|Poland|Romania|Ukraine 1
Bulgaria|Poland|Russian Federation|Serbia|Slovakia|Ukraine 1
Chile 1
Croatia|United States|Argentina|Australia|Austria|Belgium|Brazil|Bulgaria|Canada|Denmark|France|Germany|Hungary|Italy|Kuwait|Lebanon|Mexico|Netherlands|Norway|Poland|Portugal|Romania|Slovakia|Slovenia|Spain|Sweden|Switzerland|Turkey|United Kingdom 1
Czechia|Japan|Korea, Republic of|Poland|Taiwan 1
Denmark 1
Finland 1
France|Belgium|Netherlands|Spain 1
Germany|Italy 1
Germany|Spain 1
Germany|Sweden 1
Germany|Switzerland 1
Hungary|United States|Argentina|Australia|Austria|Belgium|Brazil|Canada|Denmark|Finland|France|Germany|Greece|Ireland|Israel|Italy|Latvia|Netherlands|Norway|Poland|Russian Federation|Slovenia|Spain|Sweden|Switzerland|Ukraine 1
India|Czechia|Germany|Hungary|Poland|Russian Federation|Ukraine|United Kingdom 1
Ireland|United Kingdom 1
Italy|Latvia|United States|Argentina|Australia|Austria|Belgium|Brazil|Canada|Denmark|Finland|France|Germany|Greece|Hungary|Ireland|Israel|Netherlands|Norway|Poland|Russian Federation|Slovenia|Spain|Sweden|Switzerland|Ukraine 1
Italy|United States|Australia|Belgium|Canada|France|Germany|Israel|Netherlands|Spain|United Kingdom 1
Lebanon 1
Mexico 1
Netherlands 1
Poland|United States|Argentina|Australia|Belgium|Brazil|Canada|Czechia|Denmark|Germany|Israel|Italy|Mexico|Netherlands|Russian Federation|Spain|Sweden|Ukraine|United Kingdom 1
Poland|United States|Belarus|Bosnia and Herzegovina|Bulgaria|Croatia|Czech Republic|Estonia|Georgia|Germany|Italy|Mexico|Moldova, Republic of|Romania|Russian Federation|Serbia|South Africa|Ukraine|United Kingdom 1
Portugal 1
Russian Federation|United Kingdom 1
Russian Federation|United States|Australia|Austria|Belgium|Brazil|Bulgaria|Canada|Croatia|Czech Republic|Denmark|Estonia|Finland|France|Germany|Greece|Italy|Latvia|Lebanon|Lithuania|Morocco|Netherlands|Poland|Portugal|Saudi Arabia|Serbia|Switzerland|Tunisia|Turkey|Ukraine|United Kingdom 1
Slovenia 1
United States|Argentina|Australia|Austria|Belgium|Brazil|Canada|Croatia|Czech Republic|Denmark|France|Germany|Israel|Italy|Mexico|Netherlands|Poland|Russian Federation|Serbia|Spain|Sweden|Ukraine|United Kingdom 1
United States|Argentina|Australia|Austria|Belgium|Brazil|Canada|Croatia|Czechia|Denmark|France|Germany|Israel|Italy|Mexico|Netherlands|Poland|Russian Federation|Serbia|Spain|Sweden|Ukraine|United Kingdom 1
United States|Argentina|Australia|Austria|Belgium|Brazil|Canada|Egypt|France|Germany|Greece|Hungary|Italy|Korea, Republic of|Portugal|Spain|Switzerland|United Kingdom 1
United States|Argentina|Australia|Belgium|Bulgaria|Croatia|Czechia|France|Germany|Greece|Hungary|Israel|Italy|Kuwait|Portugal|Russian Federation|Saudi Arabia|Serbia|Slovakia|Spain|Tunisia|Turkey 1
United States|Argentina|Australia|Brazil|Canada|Croatia|Czech Republic|France|Germany|Mexico|Poland|Russian Federation|Serbia|Sweden|Ukraine|United Kingdom 1
United States|Argentina|Australia|Brazil|Canada|Czech Republic|Denmark|Finland|France|Georgia|Germany|Greece|Hungary|India|Ireland|Israel|Italy|Mexico|Moldova, Republic of|Poland|Romania|Russian Federation|Serbia|Spain|Sweden|Switzerland|Ukraine|United Kingdom 1
United States|Argentina|Austria|Belgium|Croatia|Finland|France|Germany|Ireland|Italy|Mexico|Poland|Puerto Rico|Russian Federation|Spain|Turkey 1
United States|Argentina|Austria|Brazil|France|Germany|Italy|Netherlands|Russian Federation|Spain|Switzerland|United Kingdom 1
United States|Australia|Austria|Belgium|Bosnia and Herzegovina|Canada|Croatia|Czech Republic|France|Germany|Greece|Guatemala|India|Israel|Italy|Macedonia, The Former Yugoslav Republic of|Mexico|Moldova, Republic of|Netherlands|New Zealand|Poland|Romania|Serbia|Slovakia|South Africa|Switzerland|Ukraine|United Kingdom|Virgin Islands (U.S.) 1
United States|Australia|Austria|Belgium|Bulgaria|Canada|Czech Republic|Finland|France|Germany|Hungary|Israel|Italy|Netherlands|Poland|Romania|Russian Federation|Serbia|Spain|Sweden|Switzerland|Ukraine|United Kingdom 1
United States|Australia|Austria|Canada|Poland|Romania|Turkey|United Kingdom 1
United States|Austria|Belarus|Belgium|Bosnia and Herzegovina|Bulgaria|Canada|Croatia|Czechia|Estonia|France|Georgia|Germany|Greece|Hungary|Israel|Italy|Korea, Republic of|Latvia|Moldova, Republic of|Montenegro|North Macedonia|Poland|Romania|Russian Federation|Serbia|Slovakia|Spain|Ukraine|United Kingdom 1
United States|Austria|Belgium|France|Germany|Israel|Italy 1
United States|Austria|Bulgaria|Canada|Czechia|Finland|France|Germany|Hungary|Israel|Italy|Netherlands|Poland|Romania|Russian Federation|Serbia|Spain|Sweden|Switzerland|Ukraine|United Kingdom 1
United States|Austria|Canada|Czech Republic|Germany|Greece|Hungary|Israel|Poland|Slovakia|Sweden|United Kingdom 1
United States|Belarus|Belgium|Bosnia and Herzegovina|Bulgaria|Canada|Costa Rica|Croatia|Czech Republic|Estonia|France|Germany|Greece|India|Ireland|Israel|Latvia|Macedonia, The Former Yugoslav Republic of|Mexico|Moldova, Republic of|New Zealand|Poland|Puerto Rico|Romania|Serbia|Slovakia|Spain|Ukraine 1
United States|Belgium|Bulgaria|Canada|Czechia|Denmark|France|Germany|Hungary|Israel|Italy|Kuwait|Poland|Serbia|Spain|Sweden|Turkey|United Kingdom 1
United States|Belgium|Bulgaria|Canada|Czechia|Denmark|France|Germany|Italy|Mexico|Romania|Russian Federation|Serbia|Slovakia|Spain|Switzerland|Ukraine|United Kingdom 1
United States|Belgium|Bulgaria|Canada|Germany|Poland|Russian Federation|Serbia|Spain|Ukraine 1
United States|Belgium|Bulgaria|Kuwait|Lithuania|Poland|Turkey 1
United States|Belgium|Canada|Czech Republic|France|Germany|Netherlands|United Kingdom 1
United States|Belgium|Canada|Czech Republic|Germany|Greece|Japan|Poland|Russian Federation|Spain|Ukraine 1
United States|Bulgaria|Canada|Czechia|Denmark|Germany|Italy|Netherlands|Norway|Russian Federation|Spain 1
United States|Bulgaria|Czechia|France|Germany|Hungary|Israel|Poland|Romania|Russian Federation|Serbia|Slovakia|Ukraine 1
United States|Bulgaria|Estonia|Georgia|Moldova, Republic of|Russian Federation|Ukraine 1
United States|Colombia|Estonia|Hungary|Jordan|Korea, Republic of|Malaysia|Taiwan|Thailand|Turkey 1
United States|Croatia|Poland|Russian Federation|United Kingdom 1
United States|Czech Republic|Hungary|Poland 1
United States|Germany|Poland 1
United States|Germany|Spain 1
United States|Italy|Poland 1
United States|Poland|Bulgaria|Croatia|Czechia|Estonia|Georgia|Germany|Hungary|Israel|Italy|Lithuania|Romania|Russian Federation|South Africa|Ukraine|United Kingdom 1
United States|Puerto Rico 1

Sites per Study

Site_count Study_Count
1 105
2 11
3 7
4 3
5 4
6 3
7 1
8 1
9 2
10 1
11 3
12 5
13 1
14 2
15 3
16 5
17 6
18 2
19 3
20 1
21 4
22 3
23 1
26 3
29 1
30 2
31 1
33 2
34 1
35 1
37 1
38 2
43 1
46 1
47 2
48 1
49 2
53 2
54 1
55 1
56 1
57 1
60 3
61 2
62 1
63 2
64 1
65 1
67 1
71 1
72 1
79 1
80 1
81 1
82 1
84 1
86 1
88 1
90 1
97 1
98 1
101 1
105 1
113 1
115 3
117 1
123 1
131 1
133 1
160 1
163 1
170 1
176 2
184 1
191 1
193 1
199 2
230 1
248 1
284 1

Phase

Phase Study_Count
Phase 2 65
Phase 3 63
Phase 4 49
N/A 34
Phase 1 26
Phase 1/Phase 2 8
Phase 2/Phase 3 3
Early Phase 1 2

Number of Arms

Number_of_Arms Count_of_Studies
1 48
2 120
3 35
4 18
5 6
6 6
7 1
8 2
9 1
NA 13

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 30.0 10.00000 8.00 8.00 9.0000 50.0000 8.0000 8.0000
1st Qu. 42.5 35.25000 20.00 9.00 39.0000 75.0000 160.0000 58.0000
Median 55.0 50.00000 30.00 20.50 108.0000 100.0000 500.0000 151.0000
Mean 55.0 97.14706 33.52 40.25 161.2769 122.6667 672.8254 244.3673
3rd Qu. 67.5 107.50000 44.00 48.75 260.0000 159.0000 1130.5000 300.0000
Max. 80.0 900.00000 81.00 120.00 621.0000 218.0000 2244.0000 1114.0000

Trial Group Type

group_type Group_Count
Experimental 371
Active Comparator 96
Placebo Comparator 66
NA 13
Other 12
No Intervention 11
Sham Comparator 7

Intervention Model

intervention_model Study_Count
Parallel Assignment 165
Single Group Assignment 58
Crossover Assignment 17
Factorial Assignment 6
NA 3
Sequential Assignment 1

Primary Purpose

primary_purpose Study_Count
Treatment 213
Other 14
Basic Science 8
Supportive Care 6
NA 5
Diagnostic 2
Health Services Research 2

Observational Studies

Studies by Country

Country Study_Count
United States 25
NA 10
Germany 4
Argentina 3
France 3
Canada 2
Greece 2
United Kingdom 2
United States|Canada 2
Argentina|Australia|Belgium|Brazil|Canada|Czechia|Finland|France|Germany|Greece|Italy|Mexico|Netherlands|Norway|Portugal|Slovakia|Spain|United Kingdom 1
Argentina|Bahrain|Belgium|Bosnia and Herzegovina|Canada|China|Colombia|Czech Republic|Egypt|Estonia|France|Germany|Iran, Islamic Republic of|Israel|Italy|Jordan|Korea, Republic of|Kuwait|Lebanon|Libyan Arab Jamahiriya|Mexico|Netherlands|New Zealand|Norway|Pakistan|Portugal|Saudi Arabia|Singapore|Slovakia|Slovenia|Sweden|Syrian Arab Republic|Taiwan|United Arab Emirates|United Kingdom|Venezuela 1
Austria|Belgium|Bosnia and Herzegovina|Croatia|Czechia|France|Greece|Hungary|Italy|Spain|Switzerland 1
Austria|Denmark|Norway|Sweden 1
Belgium|Czechia 1
Czech Republic 1
Czech Republic|Switzerland 1
Denmark 1
Egypt 1
Finland 1
Ireland 1
Netherlands 1
Norway 1
Poland 1
Portugal 1
Spain 1
Switzerland 1
Turkey 1
United States|Argentina|Australia|Canada|Croatia|Czech Republic|France|Germany|Hungary|Italy|Spain|Switzerland|United Kingdom 1

Sites per Study

Site_count Study_Count
1 50
4 2
5 2
6 1
9 1
11 2
13 1
14 1
18 1
19 1
23 2
27 2
28 1
36 1
43 1
44 1
121 1
422 1

Enrollment Metrics

Measure Observational
Min 1.0000
1st Qu 61.0000
Median 150.0000
Mean 382.8451
3rd Qu 265.5000
Max 6620.0000

Observation Model

observational_model Study_Count
Cohort 48
Case-Only 9
Case-Control 8
Case Control 3
Other 3
NA 1

Time Perspective

time_perspective Study_Count
Prospective 58
Retrospective 8
Cross-Sectional 4
Other 1
NA 1

Registries

Studies by Country

Country Study_Count
Sweden 1
United States 1
United States|Italy 1

Sites per Study

Site_count Study_Count
1 1
3 1
38 1

Enrollment Metrics

Measure Registries
Min 80.000
1st Qu 120.000
Median 160.000
Mean 1255.333
3rd Qu 1843.000
Max 3526.000

Registry Model

observational_model Study_Count
Case-Control 1
Case-Only 1
Cohort 1

Time Perspective

time_perspective Study_Count
Prospective 2
Other 1

Follow-up

target_duration Study_Count
1 Month 1
24 Months 1
3 Years 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT03381170 An Extension of the TG1101‐RMS201 Trial https://ClinicalTrials.gov/show/NCT03381170 Active, not recruiting TG Therapeutics, Inc. 2021-09-30
NCT03401879 Retinal Neuro-vascular Coupling in Patients With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03401879 Recruiting Medical University of Vienna 2020-12-31
NCT03342638 Maximizing Outcome of Multiple Sclerosis Transplantation https://ClinicalTrials.gov/show/NCT03342638 Active, not recruiting Northwestern University 2023-01-01
NCT03283397 A Phase IIIb, Multicenter, International Study to Evaluate the Efficacy, Safety and Tolerability of EK-12 in Patients With RRMS https://ClinicalTrials.gov/show/NCT03283397 Recruiting Bosnalijek D.D 2023-03-31
NCT02515695 Phase I BP Interferon (IFN) Beta-001 https://ClinicalTrials.gov/show/NCT02515695 Completed Centre Hospitalier Universitaire Vaudois 2005-07-31
NCT03244696 Behavior and Activity Monitoring in MS https://ClinicalTrials.gov/show/NCT03244696 Recruiting Ohio State University 2020-01-31
NCT03177083 Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy https://ClinicalTrials.gov/show/NCT03177083 Active, not recruiting Biogen 2020-09-30
NCT03091569 Effects of Vitamin K on Redness Associated With Injection Site Reactions in Participants Treated With Plegridy https://ClinicalTrials.gov/show/NCT03091569 Completed Biogen 2018-01-27
NCT03085810 Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS) https://ClinicalTrials.gov/show/NCT03085810 Active, not recruiting Hoffmann-La Roche 2024-08-15
NCT03060759 Light Therapy as Treatment for Fatigue in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03060759 Completed Massachusetts General Hospital 2019-06-30
NCT03029897 E-reporting of Adverse Drug Reactions by Patients in Relapsing-remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03029897 Completed University Hospital, Caen 2019-04-24
NCT03000647 Guided Versus Non-guided Pelvic Floor Exercises for Urinary Incontinence in Relapsing-Remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03000647 Completed Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz 2016-10-31
NCT02988401 Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT02988401 Recruiting Johns Hopkins University 2021-07-31
NCT02975349 A Study of Efficacy and Safety of M2951 in Subjects With Relapsing Multiple Sclerosis https://ClinicalTrials.gov/show/NCT02975349 Active, not recruiting EMD Serono 2018-01-24
NCT02939079 Evaluating of the Effect of Fingolimod With Fish Oil on Relapsing-Remitting Multiple Sclerosis Patients https://ClinicalTrials.gov/show/NCT02939079 Completed Isfahan University of Medical Sciences 2016-09-30
NCT02914964 Dietary Approaches to Treat Multiple Sclerosis-Related Fatigue Study https://ClinicalTrials.gov/show/NCT02914964 Active, not recruiting University of Iowa 2019-10-31
NCT02861014 A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT) https://ClinicalTrials.gov/show/NCT02861014 Active, not recruiting Hoffmann-La Roche 2019-10-25
NCT02782858 Clinical Trial Assessing the HERV-W Env Antagonist GNbAC1 for Efficacy in MS https://ClinicalTrials.gov/show/NCT02782858 Completed GeNeuro SA 2017-08-31
NCT02753088 Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT02753088 Completed Biocad 2015-11-30
NCT02746744 RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis. https://ClinicalTrials.gov/show/NCT02746744 Active, not recruiting Karolinska Institutet 2021-05-31
NCT02720107 Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01) https://ClinicalTrials.gov/show/NCT02720107 Completed Novartis 2016-11-14
NCT02696590 High Dose Oral Versus Intramuscular Vitamin D3 Supplementation In Multiple Sclerosis Patients https://ClinicalTrials.gov/show/NCT02696590 Completed Isfahan University of Medical Sciences 2015-11-30
NCT02687919 Evaluation of a Modified Paleolithic Dietary Intervention in the Treatment of Relapsing-Remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT02687919 Completed University of Iowa 2014-09-30
NCT02686788 TMP001 in Relapsing-remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT02686788 Completed Fraunhofer Institute for Molecular Biology and Applied Ecology 2018-04-30
NCT02647502 A Pilot Study of Intermittent Calorie Restriction in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT02647502 Completed Johns Hopkins University 2017-06-30
NCT02637856 A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT) https://ClinicalTrials.gov/show/NCT02637856 Completed Genentech, Inc. 2019-05-03
NCT02634307 A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1 https://ClinicalTrials.gov/show/NCT02634307 Active, not recruiting Biogen 2021-05-17
NCT02587065 Plegridy Satisfaction Study in Participants https://ClinicalTrials.gov/show/NCT02587065 Completed Biogen 2017-10-02
NCT02035514 Phase I-II Clinical Trial With Autologous Bone Marrow Derived Mesenchymal Stem Cells for the Therapy of Multiple Sclerosis https://ClinicalTrials.gov/show/NCT02035514 Completed Germans Trias i Pujol Hospital 2016-07-31
NCT01093326 Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT01093326 Active, not recruiting Actelion 2021-12-15
NCT02555215 Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) https://ClinicalTrials.gov/show/NCT02555215 Completed Biogen 2018-09-24
NCT02545868 A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis https://ClinicalTrials.gov/show/NCT02545868 Active, not recruiting Hoffmann-La Roche 2017-02-14
NCT02525874 Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS). https://ClinicalTrials.gov/show/NCT02525874 Completed Biogen 2017-04-24
NCT02517788 Phase I BP Interferon (IFN) Beta-004 https://ClinicalTrials.gov/show/NCT02517788 Completed Centre Hospitalier Universitaire Vaudois 2006-07-31
NCT02506751 Open-label Study of Liothyronine in MS https://ClinicalTrials.gov/show/NCT02506751 Completed Johns Hopkins University 2017-09-18
NCT02499900 Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone® https://ClinicalTrials.gov/show/NCT02499900 Completed Teva Pharmaceutical Industries 2017-01-10
NCT02495766 Autologous Mesenchymal Stromal Cells for Multiple Sclerosis https://ClinicalTrials.gov/show/NCT02495766 Completed Banc de Sang i Teixits 2017-11-27
NCT02493049 Pilot Trial of Domperidone in Relapsing-Remitting Multiple Sclerosis (RRMS) https://ClinicalTrials.gov/show/NCT02493049 Completed University of Calgary 2019-02-28
NCT02471560 Tecfidera and the Gut Microbiota https://ClinicalTrials.gov/show/NCT02471560 Completed Biogen 2017-06-12
NCT02461069 Investigation of the Effect of Dimethyl Fumarate on T Cells in Patients With Relapsing Remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT02461069 Completed University Hospital Muenster 2018-01-24
NCT02424396 Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT02424396 Active, not recruiting Assistance Publique - Hôpitaux de Paris 2019-10-11
NCT02410200 Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS https://ClinicalTrials.gov/show/NCT02410200 Completed Biogen 2016-09-23
NCT02398461 An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse https://ClinicalTrials.gov/show/NCT02398461 Completed Acorda Therapeutics 2017-09-30
NCT02373098 Fingolimod Effect on Cytokine and Chemokine Levels https://ClinicalTrials.gov/show/NCT02373098 Completed Novartis 2017-01-18
NCT02315872 ACTH for Fatigue in Multiple Sclerosis Patients https://ClinicalTrials.gov/show/NCT02315872 Completed Providence Health & Services 2017-06-20
NCT02310048 Comparative Oral Bioavailability Study of MT-1303 https://ClinicalTrials.gov/show/NCT02310048 Completed Mitsubishi Tanabe Pharma Corporation 2015-03-31
NCT02293967 Mass Balance Study of MT-1303 https://ClinicalTrials.gov/show/NCT02293967 Completed Mitsubishi Tanabe Pharma Corporation 2014-12-31
NCT02283853 Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) https://ClinicalTrials.gov/show/NCT02283853 Active, not recruiting Biogen 2025-09-08
NCT02280876 Efficacy Study of Andrographis Paniculata Purified Standardized Extract (ApE) in Patients With Multiple Sclerosis (MS) https://ClinicalTrials.gov/show/NCT02280876 Completed Universidad Austral de Chile 2015-02-28
NCT02258217 Tolerability of Acthar for the Treatment of Multiple Sclerosis in Relapses (TAMS) https://ClinicalTrials.gov/show/NCT02258217 Completed OhioHealth 2016-06-24
NCT02255656 Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409 https://ClinicalTrials.gov/show/NCT02255656 Active, not recruiting Sanofi 2020-06-30
NCT03385356 Impact of Vitamin D Supplementation in Patients With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03385356 Completed University Medical Centre Maribor 2018-04-30
NCT02212886 Safety, Tolerability and Efficacy of Monthly Long-acting IM Injection of 80 or 40 mg GA Depot in Subjects With RRMS https://ClinicalTrials.gov/show/NCT02212886 Active, not recruiting Mapi Pharma Ltd. 2017-05-31
NCT02205489 Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA https://ClinicalTrials.gov/show/NCT02205489 Completed Sanofi 2016-04-30
NCT02193217 A Phase 1 Study to Explore the Cardiac Pharmacodynamics of MT-1303 https://ClinicalTrials.gov/show/NCT02193217 Completed Mitsubishi Tanabe Pharma Corporation 2014-12-31
NCT02142205 Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS) https://ClinicalTrials.gov/show/NCT02142205 Completed Biogen 2013-12-31
NCT02125604 Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany https://ClinicalTrials.gov/show/NCT02125604 Completed Biogen 2016-02-29
NCT02117375 EMISEP : Early Spinal Cord Lesions and Late Disability in Relapsing Remitting Multiple Sclerosis Patients https://ClinicalTrials.gov/show/NCT02117375 Active, not recruiting Rennes University Hospital 2022-04-30
NCT02090413 Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT02090413 Completed Biogen 2015-02-28
NCT02064816 A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis https://ClinicalTrials.gov/show/NCT02064816 Completed Merck KGaA, Darmstadt, Germany 2016-04-30
NCT01317004 Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change https://ClinicalTrials.gov/show/NCT01317004 Completed Novartis 2014-06-30
NCT01310166 Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT01310166 Completed Novartis 2012-07-31
NCT01307332 Advanced MRI Measures of Repair in Alemtuzumab Treated Patients https://ClinicalTrials.gov/show/NCT01307332 Completed University of British Columbia 2018-09-28
NCT01285401 Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment https://ClinicalTrials.gov/show/NCT01285401 Completed Merck KGaA, Darmstadt, Germany 2015-04-30
NCT01279876 Melatonin in Relapsing-Remitting Multiple Sclerosis Patients https://ClinicalTrials.gov/show/NCT01279876 Completed Tehran University of Medical Sciences 2014-01-31
NCT02040298 Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT02040298 Completed University of California, San Francisco 2015-09-30
NCT02019550 Rebif® Rebidose® Versus Rebiject II® Ease-of-Use https://ClinicalTrials.gov/show/NCT02019550 Completed EMD Serono 2016-01-31
NCT02010554 Development of a Talk Therapy Protocol to Help Patients Make Treatment Decisions in MS https://ClinicalTrials.gov/show/NCT02010554 Completed University of Missouri, Kansas City 2015-03-31
NCT01925690 Development of a Motivational Intervention to Improve Treatment Adherence in MS https://ClinicalTrials.gov/show/NCT01925690 Completed University of Missouri, Kansas City 2015-04-30
NCT01917019 A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT01917019 Completed Biogen 2015-10-31
NCT01890655 Extension Study of MT-1303 https://ClinicalTrials.gov/show/NCT01890655 Completed Mitsubishi Tanabe Pharma Corporation 2016-03-31
NCT01884935 PK and PD Study of Natalizumab in Pediatric Subjects With RRMS https://ClinicalTrials.gov/show/NCT01884935 Completed Biogen 2014-09-30
NCT01874145 Safety and Tolerability of Glatiramer Acetate https://ClinicalTrials.gov/show/NCT01874145 Completed Teva Pharmaceutical Industries 2014-04-30
NCT01842191 Efficacy of Fish Oil in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT01842191 Completed Coordinación de Investigación en Salud, Mexico 2011-12-31
NCT01838668 An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) https://ClinicalTrials.gov/show/NCT01838668 Completed Biogen 2015-06-16
NCT01808885 Safety Study of Olesoxime in Patients With Stable Relapsing Remitting Multiple Sclerosis Treated With Interferon Beta. https://ClinicalTrials.gov/show/NCT01808885 Completed Hoffmann-La Roche 2014-01-31
NCT01805336 Assessment of Attentional and Executive Disorders in Multiple Sclerosis Using Techniques of Virtual Reality https://ClinicalTrials.gov/show/NCT01805336 Recruiting University Hospital, Caen 2020-09-30
NCT01791244 A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device https://ClinicalTrials.gov/show/NCT01791244 Completed Merck KGaA, Darmstadt, Germany 2016-02-29
NCT01772199 Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT01772199 Completed GlaxoSmithKline 2014-09-30
NCT01742052 Dose-finding Study of MT-1303 https://ClinicalTrials.gov/show/NCT01742052 Completed Mitsubishi Tanabe Pharma Corporation 2014-07-31
NCT01738347 Assess Safety, Bio-distribution, Radiation Dosimetry and Optimize the Imaging Protocol of GEH120714 (18F) Injection in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS). https://ClinicalTrials.gov/show/NCT01738347 Completed GE Healthcare 2016-05-31
NCT01717664 Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis (RRMS) https://ClinicalTrials.gov/show/NCT01717664 Completed RedHill Biopharma Limited 2015-12-31
NCT01707992 The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) https://ClinicalTrials.gov/show/NCT01707992 Completed Teva Pharmaceutical Industries 2015-04-13
NCT01667796 Pharmacokinetics of Vitamin D in Multiple Sclerosis and in Health https://ClinicalTrials.gov/show/NCT01667796 Completed Johns Hopkins University 2014-03-31
NCT01591551 NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness https://ClinicalTrials.gov/show/NCT01591551 Completed Cornerstone Health Care, PA 2013-08-31
NCT01564511 Effects of Electromechanical Gait Trainer in Patients With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT01564511 Completed Universita di Verona 2012-02-29
NCT01538355 A Pilot Trial to Test the Feasibility of Prolonged Fasting and Ketogenic Diet in Relapsing-remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT01538355 Completed Charite University, Berlin, Germany 2013-02-28
NCT01534182 Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC) https://ClinicalTrials.gov/show/NCT01534182 Completed Novartis 2013-06-30
NCT01498887 Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy https://ClinicalTrials.gov/show/NCT01498887 Completed Novartis 2015-12-26
NCT01497262 Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT01497262 Completed Novartis 2014-04-30
NCT01490502 Vitamin D Supplementation in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT01490502 Active, not recruiting Johns Hopkins University 2021-03-31
NCT01489254 Efficacy and Safety of GTR in Comparison to Copaxone® https://ClinicalTrials.gov/show/NCT01489254 Completed Synthon BV 2015-01-31
NCT01470521 Worms for Immune Regulation of Multiple Sclerosis https://ClinicalTrials.gov/show/NCT01470521 Completed University of Nottingham 2016-01-31
NCT01466322 A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers. https://ClinicalTrials.gov/show/NCT01466322 Completed GlaxoSmithKline 2011-02-15
NCT01466114 Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition https://ClinicalTrials.gov/show/NCT01466114 Recruiting University of California, Los Angeles 2021-12-31
NCT01462318 An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT01462318 Completed Biogen 2016-01-31
NCT01457924 Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT01457924 Completed GlaxoSmithKline 2013-08-23
NCT01450124 Safety, Tolerability And Mechanism Of Action Of Boswellic Acids (BA) In Multiple Sclerosis (SABA) https://ClinicalTrials.gov/show/NCT01450124 Completed Universitätsklinikum Hamburg-Eppendorf 2014-12-31
NCT01442233 Plasma Exchanges in Multiple Sclerosis (MS) Relapses https://ClinicalTrials.gov/show/NCT01442233 Completed University Hospital, Bordeaux 2017-09-21
NCT01433250 A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT01433250 Completed Novartis 2014-06-30
NCT01431937 Assessment of Repeat Ascending Doses of GSK2018682 in Healthy Volunteers https://ClinicalTrials.gov/show/NCT01431937 Completed GlaxoSmithKline 2011-03-29
NCT01428726 A Phase IIa Study of NT-KO-003 for Multiple Sclerosis https://ClinicalTrials.gov/show/NCT01428726 Completed Neurotec Pharma 2014-01-31
NCT01424462 Healthy Volunteer Pilot Study Using 3 Types of Modified Release Formulations of Firategrast to Investigate How Quickly Absorption From the Digestive System Takes Place. https://ClinicalTrials.gov/show/NCT01424462 Completed GlaxoSmithKline 2010-07-06
NCT01420055 Fingolimod -Response According to Coping - Evaluation https://ClinicalTrials.gov/show/NCT01420055 Completed Novartis 2013-06-30
NCT01417312 Metabolic Effects of a Green Tea Extract in Multiple Sclerosis Patients https://ClinicalTrials.gov/show/NCT01417312 Completed Charite University, Berlin, Germany 2012-11-30
NCT01416363 Healthy Volunteer Study Using 3 Different Formulations of Firategrast https://ClinicalTrials.gov/show/NCT01416363 Completed GlaxoSmithKline 2011-09-17
NCT01416155 Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT01416155 Completed Biogen 2014-12-31
NCT01414634 Establish Tolerance In MS With Peptide-Coupled, Peripheral Blood Mononuclear Cells https://ClinicalTrials.gov/show/NCT01414634 Completed Universitätsklinikum Hamburg-Eppendorf 2012-10-31
NCT01405820 Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS) https://ClinicalTrials.gov/show/NCT01405820 Completed Biogen 2014-04-30
NCT01395316 Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT01395316 Completed University of Chicago 2015-10-31
NCT01392872 Cognitive Disability and Quality of Life of Patients Suffering From Multiple Sclerosis and Treatment With Immunosuppressant https://ClinicalTrials.gov/show/NCT01392872 Completed University Hospital, Clermont-Ferrand 2016-01-31
NCT01333501 Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms https://ClinicalTrials.gov/show/NCT01333501 Completed Novartis 2015-09-30
NCT04280484 Acute Intermittent Hypoxia in Persons With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT04280484 Completed Shirley Ryan AbilityLab 2019-10-10
NCT04261556 HD-tDCS to Enhance Cognitive Training in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT04261556 Active, not recruiting University of Milano Bicocca 2023-12-31
NCT04233970 Development and Evaluation of a Web-based Programme on Relapse Management for People With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT04233970 Recruiting Universitätsklinikum Hamburg-Eppendorf 2020-12-31
NCT04225312 Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT04225312 Recruiting VU University Medical Center 2023-01-02
NCT04211740 Phase II Clinical Trial of OCH-NCNP1 https://ClinicalTrials.gov/show/NCT04211740 Enrolling by invitation National Center of Neurology and Psychiatry, Japan 2020-09-30
NCT04201470 Serum Neurofilaments and GFAP in Atypical Multiple Sclerosis https://ClinicalTrials.gov/show/NCT04201470 Recruiting University Hospital, Montpellier 2021-12-31
NCT04121221 A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS https://ClinicalTrials.gov/show/NCT04121221 Recruiting Mapi Pharma Ltd. 2022-04-30
NCT04115488 Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri® https://ClinicalTrials.gov/show/NCT04115488 Recruiting Polpharma Biologics S.A. 2021-03-31
NCT04075266 A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT04075266 Recruiting Hoffmann-La Roche 2021-05-26
NCT04073940 Exploration of Brain Changes Due to a Targeted Ballet Program in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT04073940 Recruiting University of Illinois at Urbana-Champaign 2021-01-15
NCT04047628 Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) https://ClinicalTrials.gov/show/NCT04047628 Recruiting National Institute of Allergy and Infectious Diseases (NIAID) 2025-12-31
NCT03993171 31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Multiple Sclerosis (REPAIR-MS) https://ClinicalTrials.gov/show/NCT03993171 Recruiting Clene Nanomedicine 2020-10-31
NCT03979456 RItuximab Long-Term DOSE Trial in Multiple Sclerosis - RIDOSE-MS https://ClinicalTrials.gov/show/NCT03979456 Recruiting Karolinska Institutet 2024-12-20
NCT03958877 A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03958877 Recruiting Biogen 2023-03-31
NCT03910738 TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03910738 Recruiting University Hospital, Strasbourg, France 2023-05-31
NCT03872583 Understanding Magnetic Resonance Imaging in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03872583 Recruiting Universitätsklinikum Hamburg-Eppendorf 2021-03-31
NCT03768648 Cognition and MRI Markers in MS Patients With Aubagio® Treatment https://ClinicalTrials.gov/show/NCT03768648 Recruiting University Hospital, Bordeaux 2023-05-31
NCT03758820 Behavior Cognitive Therapy on Fatigue Impact in MS Patients https://ClinicalTrials.gov/show/NCT03758820 Recruiting Réseau Sep Idf Ouest 2019-03-31
NCT03691766 Photobiomodulation Therapy in Persons With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03691766 Recruiting Marquette University 2019-04-29
NCT03689972 A Study to Evaluate Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing of Natalizumab (BG00002) in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) Switching From Treatment With 4-Week Natalizumab Standard Interval Dosing (SID) in Relation to Continued SID Treatment https://ClinicalTrials.gov/show/NCT03689972 Active, not recruiting Biogen 2021-01-15
NCT03679806 Effects Aquatic Exercises on Balance and Hand Function in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03679806 Completed Dokuz Eylul University 2016-07-31
NCT03594487 Fecal Microbiota Transplantation (FMT) of FMP30 in Relapsing-Remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03594487 Recruiting University of California, San Francisco 2020-11-30
NCT03551275 Dose Escalation Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of BCD-132 in Patients With Relapsing-Remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03551275 Active, not recruiting Biocad 2019-03-31
NCT03539094 Intermittent Fasting in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03539094 Recruiting Washington University School of Medicine 2020-08-01
NCT03536559 Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03536559 Recruiting Clene Nanomedicine 2020-12-30
NCT03535298 Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS https://ClinicalTrials.gov/show/NCT03535298 Recruiting The Cleveland Clinic 2022-12-31
NCT03500328 Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial https://ClinicalTrials.gov/show/NCT03500328 Recruiting Johns Hopkins University 2023-08-01
NCT03498131 Melatonin in Patients With Multiple Sclerosis (MS). https://ClinicalTrials.gov/show/NCT03498131 Recruiting Providence Health & Services 2021-03-31
NCT03471338 Neuropsychological Management of Multiple Sclerosis: Benefits of a Computerised Semi-autonomous At-home Cognitive Rehabilitation Programme https://ClinicalTrials.gov/show/NCT03471338 Recruiting University Hospital, Caen 2020-12-31
NCT01257958 Vitamin D Pilot Study in Patients With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT01257958 Completed University of Wisconsin, Madison 2000-02-29
NCT01244139 Safety Study of BIIB033 in Subjects With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT01244139 Completed Biogen 2012-04-30
NCT01225289 Impact of Vitamin A Supplementation on Immune System in Multiple Sclerosis Patients https://ClinicalTrials.gov/show/NCT01225289 Completed Tehran University of Medical Sciences 2013-12-31
NCT01201343 Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients https://ClinicalTrials.gov/show/NCT01201343 Completed Merck KGaA, Darmstadt, Germany 2010-07-31
NCT01185821 Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT01185821 Completed Novartis 2016-10-10
NCT01167426 Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients https://ClinicalTrials.gov/show/NCT01167426 Completed Teva Pharmaceutical Industries 2010-11-30
NCT01156311 BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT01156311 Completed Biogen 2012-03-31
NCT01144052 Natalizumab De-escalation With Interferon Beta-1b https://ClinicalTrials.gov/show/NCT01144052 Completed Ospedale Civico, Lugano 2011-11-30
NCT01143441 Investigating Mechanism of Action of DAC HYP in the Treatment of High-Inflammatory Multiple Sclerosis (MS) https://ClinicalTrials.gov/show/NCT01143441 Completed National Institutes of Health Clinical Center (CC) 2017-08-11
NCT01142466 A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone https://ClinicalTrials.gov/show/NCT01142466 Completed Merck KGaA, Darmstadt, Germany 2009-12-31
NCT01116427 A Cooperative Clinical Study of Abatacept in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT01116427 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2014-06-30
NCT01111656 Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1b https://ClinicalTrials.gov/show/NCT01111656 Completed University Hospital Inselspital, Berne 2010-04-30
NCT01097668 ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis https://ClinicalTrials.gov/show/NCT01097668 Completed Apitope Technology (Bristol) Ltd. 2013-07-31
NCT01081782 A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT01081782 Completed Ono Pharmaceutical Co. Ltd 2011-12-31
NCT01071083 Treatment Interruption of Natalizumab https://ClinicalTrials.gov/show/NCT01071083 Completed Biogen 2011-11-30
NCT01067521 A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo https://ClinicalTrials.gov/show/NCT01067521 Completed Teva Pharmaceutical Industries 2012-05-08
NCT01064401 Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT01064401 Completed Biogen 2014-03-31
NCT01051817 POC-MD MRI-based Trial in Relapsing-remitting Multiple Scler https://ClinicalTrials.gov/show/NCT01051817 Completed Novartis 2012-04-30
NCT01051349 Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT01051349 Completed Biogen 2016-08-25
NCT01040117 Sensori-motor Integration Training in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT01040117 Completed Universita di Verona 2011-10-31
NCT01006265 Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT01006265 Completed Actelion 2011-06-01
NCT00947752 Safety of New Formulation of Glatiramer Acetate https://ClinicalTrials.gov/show/NCT00947752 Completed Teva Pharmaceutical Industries 2009-09-30
NCT03870763 Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants https://ClinicalTrials.gov/show/NCT03870763 Recruiting Biogen 2021-11-30
NCT00942591 Atorvastatin 40 mg in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Interferon-Beta-1b https://ClinicalTrials.gov/show/NCT00942591 Completed University Hospital Inselspital, Berne 2009-04-30
NCT00930553 An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab https://ClinicalTrials.gov/show/NCT00930553 Completed Sanofi 2016-02-29
NCT00882999 A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) https://ClinicalTrials.gov/show/NCT00882999 Completed Eli Lilly and Company 2011-02-28
NCT00879658 Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00879658 Completed Novartis 2011-05-04
NCT00871780 A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients https://ClinicalTrials.gov/show/NCT00871780 Completed Biogen 2012-07-31
NCT00870740 Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00870740 Completed Biogen 2012-05-31
NCT00869986 A Study for Patients With Relapsing Remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00869986 Completed Eli Lilly and Company 2009-09-30
NCT03846219 MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS) https://ClinicalTrials.gov/show/NCT03846219 Active, not recruiting Immunic AG 2020-05-31
NCT03093324 A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2 https://ClinicalTrials.gov/show/NCT03093324 Completed Biogen 2019-06-27
NCT01623596 Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis. https://ClinicalTrials.gov/show/NCT01623596 Completed Novartis 2015-07-13
NCT00835770 BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS) https://ClinicalTrials.gov/show/NCT00835770 Completed Biogen 2019-11-08
NCT03610139 Longitudinal Effect of Vitamin D3 Replacement on Cognitive Performance and MRI Markers in Multiple Sclerosis Patients https://ClinicalTrials.gov/show/NCT03610139 Recruiting American University of Beirut Medical Center 2020-10-31
NCT02638038 This is a Randomized Study Comparing Two Doses of INT131 ( 3 mg and 1 mg) Administered Orally (PO) Daily (QD) Versus Placebo 1 Tablet PO QD in Subjects With Treatment-naïve RRMS for ≤ 3 Years https://ClinicalTrials.gov/show/NCT02638038 Completed InteKrin Therapeutics, Inc. 2016-12-12
NCT01930708 A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes https://ClinicalTrials.gov/show/NCT01930708 Completed Biogen 2016-03-31
NCT04002934 Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT04002934 Recruiting University of California, San Francisco 2021-02-15
NCT02579681 Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012 https://ClinicalTrials.gov/show/NCT02579681 Completed Biogen 2016-12-21
NCT01705236 A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya® https://ClinicalTrials.gov/show/NCT01705236 Completed Novartis 2019-02-18
NCT03963375 Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03963375 Recruiting Washington University School of Medicine 2023-06-30
NCT00813969 Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS https://ClinicalTrials.gov/show/NCT00813969 Completed The Cleveland Clinic 2014-01-31
NCT00676715 A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00676715 Active, not recruiting Genentech, Inc. 2012-03-09
NCT00668343 Simvastatin in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Using Avonex Compared to Placebo https://ClinicalTrials.gov/show/NCT00668343 Completed Tehran University of Medical Sciences 2008-03-31
NCT00662649 Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00662649 Completed Novartis 2011-06-30
NCT00645749 Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00645749 Completed University of Wisconsin, Madison 2015-08-13
NCT00641537 CLARITY Extension Study https://ClinicalTrials.gov/show/NCT00641537 Completed EMD Serono 2011-12-31
NCT00640328 Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients https://ClinicalTrials.gov/show/NCT00640328 Completed GlaxoSmithKline 2010-05-31
NCT00616187 Atorvastatin in Relapsing-Remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00616187 Completed Charite University, Berlin, Germany 2007-06-30
NCT00594087 Eszopiclone for Improving Sleep in Multiple Sclerosis (MS) https://ClinicalTrials.gov/show/NCT00594087 Completed University of Vermont 2008-05-31
NCT00587691 Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00587691 Completed Opexa Therapeutics, Inc. 2007-06-30
NCT00559702 Safety Study of Natalizumab to Treat Multiple Sclerosis (MS) https://ClinicalTrials.gov/show/NCT00559702 Completed Biogen 2011-11-30
NCT00548405 Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two https://ClinicalTrials.gov/show/NCT00548405 Completed Sanofi 2011-09-30
NCT00534261 Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a? https://ClinicalTrials.gov/show/NCT00534261 Completed Biogen NA
NCT00530348 Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One https://ClinicalTrials.gov/show/NCT00530348 Completed Sanofi 2011-04-30
NCT00525668 Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study) https://ClinicalTrials.gov/show/NCT00525668 Completed Charite University, Berlin, Germany 2012-11-30
NCT00509145 Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS) https://ClinicalTrials.gov/show/NCT00509145 Completed Teva Pharmaceutical Industries 2010-11-30
NCT00493116 Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta https://ClinicalTrials.gov/show/NCT00493116 Completed Biogen 2009-12-31
NCT00492765 Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00492765 Completed Biogen 2010-04-30
NCT00492466 Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies https://ClinicalTrials.gov/show/NCT00492466 Completed Biogen 2006-08-31
NCT00459667 BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose https://ClinicalTrials.gov/show/NCT00459667 Completed Bayer 2008-03-31
NCT00451451 Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00451451 Completed Biogen 2011-08-31
NCT00451204 A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS) https://ClinicalTrials.gov/show/NCT00451204 Completed University of California, Los Angeles 2014-07-31
NCT00441103 A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00441103 Completed Merck KGaA, Darmstadt, Germany 2008-11-30
NCT00428584 RNF and Betaseron® Tolerability Study https://ClinicalTrials.gov/show/NCT00428584 Completed EMD Serono 2007-11-30
NCT00420212 Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00420212 Completed Biogen 2011-02-28
NCT00395317 Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis (MS) https://ClinicalTrials.gov/show/NCT00395317 Completed GlaxoSmithKline 2009-08-31
NCT00390221 Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00390221 Completed Biogen 2011-05-31
NCT00382629 BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00382629 Completed Bayhill Therapeutics NA
NCT00367484 Study To Evaluate The Immunogenicity And Safety Of r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00367484 Completed Merck KGaA, Darmstadt, Germany 2006-01-31
NCT00360906 Omega-3 Fatty Acid Treatment in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00360906 Completed Haukeland University Hospital NA
NCT00355134 Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00355134 Completed Novartis 2011-06-30
NCT00349193 A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod https://ClinicalTrials.gov/show/NCT00349193 Completed Teva Pharmaceutical Industries 2006-06-30
NCT00340834 Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase https://ClinicalTrials.gov/show/NCT00340834 Completed Novartis 2011-07-31
NCT00337779 Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA). https://ClinicalTrials.gov/show/NCT00337779 Completed Teva Pharmaceutical Industries 2008-10-31
NCT00317941 Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif https://ClinicalTrials.gov/show/NCT00317941 Completed Bayer 2008-04-30
NCT00315367 A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties https://ClinicalTrials.gov/show/NCT00315367 Completed Neurognostics NA
NCT00306592 Natalizumab Re-Initiation of Dosing https://ClinicalTrials.gov/show/NCT00306592 Completed Biogen 2007-12-31
NCT00292266 A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS) https://ClinicalTrials.gov/show/NCT00292266 Completed EMD Serono 2002-06-30
NCT00292253 Tolerability of Rebif® Injection With and Without the Use of Rebiject™Mini in Relapsing-Remitting Multiple Sclerosis Subjects https://ClinicalTrials.gov/show/NCT00292253 Completed EMD Serono 2002-12-31
NCT00289978 Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00289978 Completed Novartis 2009-07-31
NCT00288626 High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study https://ClinicalTrials.gov/show/NCT00288626 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2015-11-30
NCT00276341 Study on the Effectiveness of EGb 761® vs Placebo Used for Cognitive Impairment in Patients With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00276341 Completed Ipsen NA
NCT00245622 Autologous T Cell Vaccine (TCV) for Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00245622 Completed Opexa Therapeutics, Inc. 2008-09-30
NCT00242177 Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability https://ClinicalTrials.gov/show/NCT00242177 Completed University of Illinois at Chicago NA
NCT00235989 Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00235989 Completed Bayer 2008-01-31
NCT00228397 Study Evaluating CCI-779 in Relapsing Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00228397 Completed Wyeth is now a wholly owned subsidiary of Pfizer 2005-11-30
NCT00220779 Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00220779 Completed Grifols Therapeutics LLC 2005-02-28
NCT00213135 A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) https://ClinicalTrials.gov/show/NCT00213135 Completed EMD Serono 2008-11-30
NCT00211887 Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx https://ClinicalTrials.gov/show/NCT00211887 Completed Icahn School of Medicine at Mount Sinai 2012-04-30
NCT00206648 An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS https://ClinicalTrials.gov/show/NCT00206648 Completed Bayer NA
NCT00203073 A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis. https://ClinicalTrials.gov/show/NCT00203073 Completed Teva Pharmaceutical Industries 2005-01-31
NCT00203021 Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness https://ClinicalTrials.gov/show/NCT00203021 Completed Teva Pharmaceutical Industries 2018-02-28
NCT00200655 Safety and Efficacy of Pravastatin in Relapsing-remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00200655 Completed Nantes University Hospital NA
NCT00168766 Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS https://ClinicalTrials.gov/show/NCT00168766 Completed Biogen 2008-11-30
NCT01767701 Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis https://ClinicalTrials.gov/show/NCT01767701 Completed Queen Mary University of London 2014-09-30
NCT00112034 AVONEX® Combination Trial - “ACT” https://ClinicalTrials.gov/show/NCT00112034 Completed Biogen 2006-06-30
NCT00099502 BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients https://ClinicalTrials.gov/show/NCT00099502 Completed Bayer NA
NCT00097760 Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00097760 Completed Biogen 2004-03-31
NCT00097331 Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00097331 Completed GlaxoSmithKline 2006-07-31
NCT00097188 A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00097188 Completed Genentech, Inc. NA
NCT00078338 Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00078338 Completed EMD Serono 2006-11-28
NCT00076934 Safety of RG2077 in Patients With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00076934 Completed National Institute of Allergy and Infectious Diseases (NIAID) NA
NCT00071838 Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00071838 Completed National Institutes of Health Clinical Center (CC) 2007-10-04
NCT00067327 Treatment of Multiple Sclerosis Using Over the Counter Inosine https://ClinicalTrials.gov/show/NCT00067327 Completed National Center for Complementary and Integrative Health (NCCIH) NA
NCT00050778 A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00050778 Completed Sanofi 2007-09-30
NCT00030966 Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00030966 Completed Biogen 2005-04-30
NCT00027300 Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00027300 Completed Biogen 2004-11-30
NCT00837785 A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With MS https://ClinicalTrials.gov/show/NCT00837785 Completed Biogen 2009-10-31

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT03975413 Fecal Microbiota Transplantation (FMT) in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03975413 Active, not recruiting Rush University Medical Center 2020-04-01
NCT03302442 Comparison of Oral Molecules Preventing Relapses in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03302442 Completed Nantes University Hospital 2017-08-01
NCT03284970 Retrospective Study to Determine Effect of Rebif and Tecfidera on Infections and Lymphocytes https://ClinicalTrials.gov/show/NCT03284970 Completed EMD Serono 2018-05-11
NCT03205280 Clinical Decision Support System (CADIMS) for MS Diagnostic https://ClinicalTrials.gov/show/NCT03205280 Recruiting Rennes University Hospital 2020-03-01
NCT03157830 Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab https://ClinicalTrials.gov/show/NCT03157830 Recruiting Providence Health & Services 2021-06-30
NCT03004079 Clinical Importance of Glucose Regulation in Relapsing MS https://ClinicalTrials.gov/show/NCT03004079 Recruiting University of Virginia 2020-09-30
NCT02776072 Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS) https://ClinicalTrials.gov/show/NCT02776072 Completed Biogen 2016-12-31
NCT02677077 Clinical Disease Activity With Long Term Natalizumab Treatment https://ClinicalTrials.gov/show/NCT02677077 Completed Biogen 2016-08-18
NCT02652091 Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction https://ClinicalTrials.gov/show/NCT02652091 Completed Bayer 2017-08-11
NCT02598167 Participants Preferences to Disease Modifying Agents in Relapsing Remitting Multiple Sclerosis Condition https://ClinicalTrials.gov/show/NCT02598167 Completed Hoffmann-La Roche 2016-02-23
NCT02588053 Does Long-Term Natalizumab (NTZ) Therapy Normalize Brain Atrophy Rates and Quality of Life (QOL) in Relapsing Remitting Multiple Sclerosis (RRMS)? https://ClinicalTrials.gov/show/NCT02588053 Completed University of Colorado, Denver 2018-12-31
NCT00493298 Tysabri Observational Program https://ClinicalTrials.gov/show/NCT00493298 Active, not recruiting Biogen 2029-01-03
NCT02549703 Mitochondrial Dysfunction and Disease Progression https://ClinicalTrials.gov/show/NCT02549703 Completed Icahn School of Medicine at Mount Sinai 2018-09-27
NCT02335892 PROFILE - Evaluation of QoL and PRO Outcomes in Patients Taking Fingolimod https://ClinicalTrials.gov/show/NCT02335892 Completed Novartis 2017-02-01
NCT02308670 Evaluate the Effect of Switching From Daily Injections of 20mg Glatiramer Acetate (GA) to 40mg GA Three Times a Week in Subjects With Relapsing-remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT02308670 Completed University at Buffalo 2016-10-31
NCT02277964 Disease Control in RRMS Transferring Treatment From Natalizumab to Fingolimod https://ClinicalTrials.gov/show/NCT02277964 Completed University Hospital, Basel, Switzerland 2016-08-31
NCT02275741 Study to Investigate the Immune Response and Safety of Prophylactic Vaccines in Patients Treated for Multiple Sclerosis https://ClinicalTrials.gov/show/NCT02275741 Completed University of Rostock 2015-09-30
NCT02247310 BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon https://ClinicalTrials.gov/show/NCT02247310 Completed Bayer 2016-07-19
NCT02159573 Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab) https://ClinicalTrials.gov/show/NCT02159573 Completed Biogen 2015-01-31
NCT02076841 Tolerability and Quality of Life Study in Participants Who Switched to Avonex Pen https://ClinicalTrials.gov/show/NCT02076841 Completed Biogen 2016-02-29
NCT01945359 Pilot Study to Assess Disease Stability in a Natalizumab to Dimethyl Fumarate Crossover Design https://ClinicalTrials.gov/show/NCT01945359 Completed Rocky Mountain MS Research Group, LLC 2014-09-30
NCT01943526 Ireland Natalizumab (TYSABRI) Observational Program https://ClinicalTrials.gov/show/NCT01943526 Completed Biogen 2017-12-31
NCT01909492 Relaxin in Multiple Sclerosis (MS) https://ClinicalTrials.gov/show/NCT01909492 Recruiting Providence Health & Services 2019-09-30
NCT01628315 Assessment of Lesion Activity Analysis in the Avonex- Steroid Azathioprine (ASA) Study https://ClinicalTrials.gov/show/NCT01628315 Completed University at Buffalo 2009-03-31
NCT01485003 Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants https://ClinicalTrials.gov/show/NCT01485003 Completed Biogen 2018-11-26
NCT01456416 Glatiramer Acetate for Multiple Sclerosis With Autoimmune Comorbidities https://ClinicalTrials.gov/show/NCT01456416 Completed University of Southern California 2013-04-30
NCT04450030 Immunoadsorption Versus High-dose Intravenous Corticosteroids in Relapsing Multiple Sclerosis https://ClinicalTrials.gov/show/NCT04450030 Recruiting University Hospital Muenster 2020-08-31
NCT04221191 Dimethyl Fumarate (DMF, Tecfidera®) Persistence in RR-MS Patients Included in the French Patient Support Program OroSEP https://ClinicalTrials.gov/show/NCT04221191 Recruiting Biogen 2021-08-19
NCT03347370 A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03347370 Completed Biogen 2019-07-31
NCT03942952 PEDIATRIC SONICS: Pediatric Study of Neuropsychology and Imaging in CNS Demyelinating Syndromes. https://ClinicalTrials.gov/show/NCT03942952 Recruiting University of Texas Southwestern Medical Center 2022-05-31
NCT03718247 Utilization of the Ketogenic Diet in Patient With Relapsing Remitting MS https://ClinicalTrials.gov/show/NCT03718247 Recruiting University of Virginia 2022-10-31
NCT03718026 The Reliability, Validity, and Responsiveness of the Timed 360° Turn Test in Patients With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03718026 Completed Gazi University 2018-11-16
NCT03653585 Cortical Lesions in Patients With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT03653585 Recruiting Danish Research Centre for Magnetic Resonance 2020-07-31
NCT03562975 Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus https://ClinicalTrials.gov/show/NCT03562975 Recruiting University of South Florida 2020-08-31
NCT03561402 Biomarkers and Disease Activity in Patients Treated With Teriflunomide (Aubagio) https://ClinicalTrials.gov/show/NCT03561402 Recruiting McGill University 2018-08-30
NCT03464448 Mechanistic Studies of Teriflunomide in RRMS https://ClinicalTrials.gov/show/NCT03464448 Recruiting University of Michigan 2021-10-31
NCT01235455 Portuguese Observational Survey to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon by Using Elements of the BetaPlus Program - Nurse Support, Auto-injectors https://ClinicalTrials.gov/show/NCT01235455 Completed Bayer NA
NCT01158183 Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple Sclerosis https://ClinicalTrials.gov/show/NCT01158183 Completed Bayer 2009-09-30
NCT01142583 A Canadian Study Assessing the Utility of the Treatment Optimization Recommendations in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT01142583 Completed Merck KGaA, Darmstadt, Germany 2009-08-31
NCT01142518 An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With Mitoxantrone https://ClinicalTrials.gov/show/NCT01142518 Completed Merck KGaA, Darmstadt, Germany 2009-03-31
NCT01142492 A Postmarketing Surveillance (PMS) Study to Evaluate the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis (MS) With Interferon Beta 1a (Rebif®) https://ClinicalTrials.gov/show/NCT01142492 Completed Merck KGaA, Darmstadt, Germany 2008-07-31
NCT01142453 An Observational Study Evaluating Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in Multiple Sclerosis (MS) Patients https://ClinicalTrials.gov/show/NCT01142453 Completed Merck KGaA, Darmstadt, Germany 2008-06-30
NCT01141751 An Observational Study Comparing Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL) and Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) in Relapsing Multiple Sclerosis (RMS) Patients on Long-term Rebif® Therapy https://ClinicalTrials.gov/show/NCT01141751 Completed Merck KGaA, Darmstadt, Germany 2011-06-30
NCT01125475 A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) Subjects https://ClinicalTrials.gov/show/NCT01125475 Completed Merck KGaA, Darmstadt, Germany 2012-03-31
NCT01112345 An Observational Study for the Assessment of Compliance and Persistence to Rebif® Therapy of Patients With Relapsing-remitting Multiple Sclerosis (MS) and Evaluation of Potential Factors Influencing These Parameters https://ClinicalTrials.gov/show/NCT01112345 Completed Merck KGaA, Darmstadt, Germany 2012-09-30
NCT01110993 An Observational Study to Evaluate Quality of Life (QoL) and Influence of Cognitive Status on QoL in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) During 2 Years Treatment With Rebif New Formulation (RNF) https://ClinicalTrials.gov/show/NCT01110993 Completed Merck KGaA, Darmstadt, Germany 2013-09-30
NCT01108887 An Observational Study for the Assessment of Adherence, Effectiveness and Convenience of Rebif® Treatment in Relapsing Multiple Sclerosis Patients Using RebiSmart™. https://ClinicalTrials.gov/show/NCT01108887 Completed Merck KGaA, Darmstadt, Germany 2013-01-31
NCT01080053 Sexual Dysfunction, Disability and Quality of Life in Patients With Multiple Sclerosis (MS) https://ClinicalTrials.gov/show/NCT01080053 Completed Merck KGaA, Darmstadt, Germany 2013-05-31
NCT01080040 To Assess the Prevalence of Spasticity and the Impact on the Quality of Life in Multiple Sclerosis Patients https://ClinicalTrials.gov/show/NCT01080040 Completed Merck KGaA, Darmstadt, Germany 2013-03-31
NCT01080027 Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR) https://ClinicalTrials.gov/show/NCT01080027 Completed Merck KGaA, Darmstadt, Germany 2011-06-30
NCT01080001 A Observational, Prospective Study to Assess the Impact of Fatigue in the Quality of Life of Patients With Multiple Sclerosis in Argentina https://ClinicalTrials.gov/show/NCT01080001 Completed Merck KGaA, Darmstadt, Germany 2010-12-31
NCT01075880 Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif® https://ClinicalTrials.gov/show/NCT01075880 Completed Merck KGaA, Darmstadt, Germany 2013-06-30
NCT01044576 Patient Research Cohort: Rapidly Evolving Multiple Sclerosis https://ClinicalTrials.gov/show/NCT01044576 Completed Imperial College London 2012-11-30
NCT01020370 Exploratory Study to Investigate the Reparative and Regenerative Potential of Alemtuzumab in Relapsing-Remitting Multiple Sclerosis Patients Participating in the CARE MS I and MS II Studies https://ClinicalTrials.gov/show/NCT01020370 Completed Wayne State University NA
NCT00937677 Effect of Tysabri in Patients With Relapsing-Remitting Multiple Sclerosis: A Follow-up Magnetization Transfer Imaging (MTI) Study https://ClinicalTrials.gov/show/NCT00937677 Completed University at Buffalo 2009-12-31
NCT00919217 Exploratory Study on the Timing of Multiple Sclerosis (MS) Symptoms https://ClinicalTrials.gov/show/NCT00919217 Recruiting University of Louisville 2020-12-31
NCT00902135 Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH) https://ClinicalTrials.gov/show/NCT00902135 Completed Bayer 2013-12-31
NCT00888277 Bayer/Cognitive Assessments With Multiple Sclerosis Subjects https://ClinicalTrials.gov/show/NCT00888277 Completed University of Louisville 2009-12-31
NCT00884481 Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS https://ClinicalTrials.gov/show/NCT00884481 Completed Biogen 2011-06-30
NCT00859482 Differential Immune Effects of Natalizumab https://ClinicalTrials.gov/show/NCT00859482 Completed Cantonal Hospital of St. Gallen 2007-07-31
NCT04157283 Sexual Dysfunction in Patients With Relapsing Remitting Multiple Sclerosis and Associated Comorbidities https://ClinicalTrials.gov/show/NCT04157283 Recruiting Mansoura University Hospital 2020-05-05
NCT04115930 Correlation Between Daily Physical Activity and Disability, Fatigue, Cognition and Quality of Life in MS Patients https://ClinicalTrials.gov/show/NCT04115930 Completed University of Eastern Finland 2019-06-13
NCT02823951 Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif® https://ClinicalTrials.gov/show/NCT02823951 Completed IMS HEALTH GmbH & Co. OHG 2017-04-30
NCT00787657 Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment https://ClinicalTrials.gov/show/NCT00787657 Completed Bayer 2013-09-30
NCT00675883 COMPliance With Avonex® PS in Patients With Relapsing-Remitting MS https://ClinicalTrials.gov/show/NCT00675883 Completed Biogen 2011-12-31
NCT00492570 GER-009-06-AVX Early Therapy in Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00492570 Completed Biogen 2007-10-31
NCT00461396 Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron https://ClinicalTrials.gov/show/NCT00461396 Completed Bayer 2009-06-30
NCT00391352 fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to Controls https://ClinicalTrials.gov/show/NCT00391352 Completed Waukesha Memorial Hospital 2012-08-31
NCT00232193 Safety/Effectiveness of Adding Monthly Dexamethasone to Weekly Avonex for MS https://ClinicalTrials.gov/show/NCT00232193 Completed Providence Multiple Sclerosis Center 2008-12-31
NCT00206635 Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00206635 Completed Bayer NA
NCT00203086 A Study to Evaluate the Long Term Safety and Effectiveness of Novantrone Therapy Followed by Copaxone Treatment for Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00203086 Completed Teva Pharmaceutical Industries 2009-10-31
NCT00818038 A Proof of Concept Study to Evaluate the Effectiveness of Tysabri in Relapsing Remitting Multiple Sclerosis (RRMS) Patient Bladder Function https://ClinicalTrials.gov/show/NCT00818038 Completed Biogen 2011-03-31

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT03193866 COMparison Between All immunoTherapies for Multiple Sclerosis. https://ClinicalTrials.gov/show/NCT03193866 Active, not recruiting Karolinska Institutet 2022-06-30
NCT02633033 Observational Registry of Acthar Gel for Participants With Multiple Sclerosis Relapse https://ClinicalTrials.gov/show/NCT02633033 Completed Mallinckrodt 2019-05-09
NCT04380220 Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis https://ClinicalTrials.gov/show/NCT04380220 Active, not recruiting Regina Elena Cancer Institute 2020-08-31